Navigation Links
Nephros Announces Completion of Reverse Stock Split
Date:3/11/2011

RIVER EDGE, N.J., March 11, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that a previously approved and announced 1-for-20 reverse split of its common stock will take effect at the start of trading on Monday, March 14, 2011. Nephros common stock will be quoted on the OTC Bulletin Board on a split-adjusted basis beginning upon the opening of trading on March 14.  Nephros shares will continue to trade under the symbol "NEPH.OB."

As a result of the reverse stock split, every 20 shares of Nephros common stock issued and outstanding immediately prior to the effective time, which was 5:00 p.m. on March 11, 2011, will be converted into one share of common stock. Fractional shares will not be issued and stockholders who otherwise would have been entitled to receive a fractional share as a result of the reverse stock split will receive an amount in cash equal to $0.04 per pre-split share for such fractional interests. The number of shares of Nephros common stock issued and outstanding will be reduced from approximately 201,300,000 pre-split to approximately 10,100,000 post-split.  The reverse stock split was effected in connection with the company's recently completed rights offering and private placement.

Letters of transmittal are expected to be sent to stockholders by the company's transfer agent, Continental Stock Transfer and Trust Company, shortly after the effectiveness of the reverse stock split. No action by Nephros stockholders is required prior to receipt of these letters.

The reverse stock split was approved by the Nephros stockholders at the company's annual meeting held on January 10, 2011. The number of shares of common stock subject to outstanding stock warrants and opt
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions
2. Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions
3. Nephros Extends Rights Offering
4. Nephros Has Commenced Rights Offering
5. Nephros Rights Offering Registration Statement Declared Effective
6. Nephros Reports 2010 Third Quarter Financial Results
7. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
10. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
11. Nephros Reports 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 Valeant Pharmaceuticals International, ... today announced the expiration of the tender offer (the ... to purchase all of the outstanding shares of Salix ... price of $173.00 per share in cash, without interest, ... midnight, Eastern time, on April 1, 2015.  Valeant expects ...
(Date:4/1/2015)... Yew Bio-Pharm Group, Inc. ("Yew Bio" or the "Company") (OTCBB: ... raw materials used in the manufacture of traditional Chinese medicine ... financial results for the three- and twelve-months ended December 31, ... 31,Twelve Months Ended December 31, 2014 , 2013 ... $686,669 , $998,934 $4,043,290 , ...
(Date:3/31/2015)... March 31, 2015 Neurocrine Biosciences, Inc. (Nasdaq: ... into an exclusive collaboration and licensing agreement for the ... Japan and other select Asian ... Tanabe intends to initially develop NBI-98854 in ... disease and tardive dyskinesia. Neurocrine retains full commercial rights ...
Breaking Medicine Technology:Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 2Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd. 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 2Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 3Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 4Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 5Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 6Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 7Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 8Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 9Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 10Yew Bio-Pharm Group Reports 2014 Fourth Quarter And Full Year Financial Results 11Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
... Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian,biotechnology company Avexa ... blinded phase which,represents the first 24 week segment ... into the open-label section of the,trial (weeks 24 ... twice a day as part of their daily ...
... LAINATE, Italy - July 4, 2007 - Cosmo ... its,phase II/III study with CB-01-11 (Rifamycin SV MMX(tm)) ... that is not absorbed when taken in tablet ... delivers the active,ingredient into the colon, bacteria in ...
Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
(Date:4/1/2015)... 01, 2015 When you’re suffering from back ... finding some relief. Identifying the causes of lingering back or ... cases, the cause of chronic back pain is due to ... diagnosable causes of back pain and offers many possible treatments, ... president of Atlantic Spine Center . , Dr. Liu ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Nike Golf ... Development Camps in Arizona and Florida. These programs are ... lower their score in a golf-intensive environment and to ... led by University of Arizona coaching legend, Rick LaRose, ... on the knowledge gaps as it pertains to the ...
(Date:3/31/2015)... York (PRWEB) April 01, 2015 Bon ... of Charity to the Schervier Nursing Care Center family ... of Mary the Queen in Yonkers which is scheduled ... Jane Iannucelli, SC, president of the Sisters of Charity ... Charity board of directors to place their Sisters at ...
(Date:3/31/2015)... 2015 Cosmetic Town, one of the ... proudly enduring adding news to its site while it ... of plastic surgery and cosmetic medicine better use and ... interconnected sections, the Cosmetic Town community is tingling at ... Cosmetic Town site navigation, News and Blog section, will ...
(Date:3/31/2015)... Karen A. Daley, Ph.D. will address graduates ... Commencement ceremony on May 9, 2015 and will ... of her eminent career as a nurse, public health ... and senior staff nurse at Brigham and Women’s Hospital ... roles, including President of the American Nurses Association in ...
Breaking Medicine News(10 mins):Health News:Demystifying Facet Joint Syndrome 2Health News:Demystifying Facet Joint Syndrome 3Health News:Demystifying Facet Joint Syndrome 4Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 2Health News:US Sports Camps and Nike Golf Camps to Host Golf Development Camps in Arizona and Florida 3Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2Health News:Cosmetic Town is Now Transforming so Consumer can Better Navigate 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 2Health News:Rivier University to recognize nurse leader, educator and safety advocate at 80th Commencement on May 9th 3
... children are to be weighed, measured and interviewed regarding ... //the growing menace of childhood obesity. The Australian Health ... aged between 7 and 15, are either overweight or ... of heart disease and diabetes. Federal Health Minister Tony ...
... surgeon and a researcher at the children hospital of ... dose anti rejection protocol //has appreciably improved the outcomes ... by Rakesh Sindhi, MD, Co-Director of Pediatric Transplantation, and ... new protocol reduces drug doses and eliminates steroids altogether ...
... up with a new preventive strategy to fight childhood obesity.// ... concern for both the parent and the society. In the ... a program in Meade County, Ky to fight childhood obesity. ... researchers are planning to launch the new program among the ...
... According to the scientist from the Victorian Breast Cancer Research ... have undergone some mutation give rise to the most aggressive ... Hall Institute researchers were working on mouse models when they ... for the female hormones oestrogen or progesterone. This characteristic is ...
... revealed that many popular breakfast cereals contain high levels of ... brands of cereals that were checked for sugar, salt and ... than three-quarters had a high level of sugars, while a ... had high level of saturated fat. ...
... recent announcements by Health Minister, Tony Abbott, to tackle ... has failed to impress AMA President Mukesh// Haikerwal. The ... so that problem can be tackled more effectively. ... new ministerial taskforce for an anti-obesity campaign involving industry ...
Cached Medicine News:Health News:Low Dose Anti Rejection Protocol Helps Intestinal Transplant Recipients 2Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
... Penilab IV and the Penilab V have an exceptionally ... 1060 is similar to the Model 1061 shown below, ... be added later. The Penilab V has a ... the accessories you'll need to get started. Latex ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... MRI-Compatible Anesthesia System is perfect for larger surgery ... type of anesthetic agent. , ,The Integra ... its wider stance, has a larger work area. ... is utilized in both the Integra I and ...
... Market leader in soft tissue repair in ... has developed the latest evolution in orthopedic ... ORTHOCORD Suture is as strong as any ... importantly, ORTHOCORD Suture handles like ETHIBOND®., ,ORTHOCORD ...
Medicine Products: